Epoprostenol (Prostacyclin) therapy in HIV-associated pulmonary hypertension

American Journal of Respiratory and Critical Care Medicine

Volumn 162, Issue 5, 2000, Pages 1846-1850

  Aguilar, Robin V ^a   Farber, Harrison W ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; PROSTACYCLIN;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; HEART OUTPUT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; TREATMENT OUTCOME;

EID: 0033679134     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.162.5.2004042     Document Type: Article

References (32)

1. Microvascular cytomegalovirus endothelialitis of the lung: A possible cause of secondary pulmonary hypertension in a patient with AIDS
2. Primary pulmonary hypertension in association with human immunodeficiency virus infection: A possible viral etiology for some forms of hypertensive pulmonary arteriopathy
3. Severe pulmonary hypertension and cor pulmonale in the acquired immunodeficiency syndrome
4. Primary pulmonary hypertension associated with human immunodeficiency viral infection
5. Primary pulmonary hypertension in HIV infection
6. Pulmonary hypertension and human immunodeficiency virus infection: Two reports and a review of the literature
7. HIV and pulmonary hypertension: A review
8. Pulmonary hypertension in patients human immunodeficiency virus infection: Comparison with primary pulmonary hypertension
9. Primary pulmonary hypertension in HIV infection: An outcome determined by particular HLA class II alleles
10. HIV-associated primary pulmonary hypertension: A case control study
11. Human immunodeficiency virus infection and pulmonary hypertension: Two new cases and a review of 86 reported cases
12. High dose titration of calcium channel blocking agents for primary pulmonary hypertension: Guidelines for short-term drug testing
13. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension
14. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin)
15. Survival in primary pulmonary, hypertension with long-term continuous intravenous prostacyclin
16. Role of prostacyclin in the treatment of primary pulmonary hypertension
17. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
18. Primary pulmonary hypertension: Improved long-term effects and survival with continuous intravenous epoprostenol infusion
19. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension
20. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): Results of a randomized trial
21. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension
22. Prostacyclin for HIV-associated pulmonary hypertension
23. Primary pulmonary hypertension: A national prospective study
24. The acute effects of prostacyclin on pulmonary hemodynamics in patients with pulmonary hypertension secondary to systemic sclerosis
25. Treatment of severe pulmonary hypertension secondary to connective tissue diseases with continuous IV epoprostenol (prostacyclin)
26. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: A case series
27. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension
28. Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension
29. The perioperative management of portopulmonary hypertension with nitric oxide and epoprostenol
30. Systemic sclerosis-associated pulmonary hypertension: Acute and long-term effects of epoprostenol (prostacyclin)
31. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus
32. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: A randomized, controlled trial